How should I manage an 84-year-old woman with impaired renal function (eGFR 42 mL/min/1.73 m²), on furosemide 40 mg twice daily, mild hypermagnesemia, recently discharged after deep vein thrombosis, pulmonary embolism, and congestive heart failure exacerbation?

Management of 84-Year-Old with CHF Exacerbation, DVT/PE, and Moderate CKD

Continue furosemide 40 mg BID with close monitoring of renal function and electrolytes, initiate anticoagulation for DVT/PE, optimize guideline-directed medical therapy for heart failure, and address the mild hypermagnesemia by discontinuing any magnesium-containing supplements while monitoring levels. 1

Immediate Priorities

Anticoagulation for DVT/PE

• Initiate a direct oral anticoagulant (DOAC) as first-line therapy over warfarin for the acute DVT/PE, provided there are no contraindications 1
• With eGFR 42 mL/min/1.73 m², most DOACs remain appropriate (apixaban, rivaroxaban, or edoxaban are preferred; avoid if creatinine clearance <30 mL/min) 1
• If DOACs are contraindicated due to renal function concerns, use low molecular weight heparin (LMWH) bridged to warfarin with target INR 2.0-3.0 1
• Plan for at least 3 months of therapeutic anticoagulation, with consideration for extended therapy given unprovoked nature if no major reversible risk factors identified 1

Diuretic Management

• Continue furosemide 40 mg BID as the current regimen is appropriate for her eGFR and twice-daily dosing is preferred over once-daily in patients with reduced GFR 1
• Monitor for signs of adequate decongestion: resolution of peripheral edema, orthopnea, and dyspnea 1
• If diuretic resistance develops, consider:
  • Increasing furosemide dose (can titrate up to 600 mg/day with careful monitoring) 2
  • Adding a thiazide diuretic for synergistic effect (though use cautiously with eGFR <30 mL/min) 1
  • Switching to torsemide if concerned about furosemide bioavailability, though recent evidence shows no superiority 3

Hypermagnesemia Management

• Magnesium 2.5 mg/dL is mildly elevated but generally not clinically significant in the absence of symptoms 4, 5
• Discontinue any magnesium-containing supplements, laxatives (especially magnesium oxide), or antacids 4, 5
• Loop diuretics like furosemide typically cause hypomagnesemia, not hypermagnesemia; the elevated level may reflect recent supplementation or reduced renal clearance 5
• Monitor magnesium levels weekly initially, as hypermagnesemia in the setting of moderate CKD can worsen with further renal decline 5
• If magnesium rises above 4 mg/dL or symptoms develop (hyporeflexia, weakness, hypotension), consider calcium gluconate and increased diuresis 4

Guideline-Directed Medical Therapy Optimization

Heart Failure Medications

• Initiate or optimize ACE inhibitor/ARB or angiotensin receptor-neprilysin inhibitor (ARNI) as first-line therapy for HFrEF 1

  • Start at low dose and uptitrate gradually 1
  • Accept up to 30% increase in creatinine without stopping therapy 1
  • Monitor renal function and potassium 1-2 weeks after initiation and dose changes 1

• Add beta-blocker once volume status optimized and patient hemodynamically stable 1

  • Initiate at low dose after discontinuation of intravenous agents 1
  • Beta-blockers reduce mortality in HFrEF across all NYHA classes 1

• Consider mineralocorticoid receptor antagonist (MRA) such as spironolactone for advanced heart failure 1

  • Use cautiously with eGFR 42 mL/min; monitor potassium closely (risk of hyperkalemia, especially with concurrent RAAS inhibition) 1
  • Avoid if potassium >5.0 mmol/L or creatinine >2.5 mg/dL 1

• Consider SGLT2 inhibitor as part of contemporary guideline-directed medical therapy for HFrEF, which has shown cardiovascular and renal benefits 1

Monitoring Strategy

Laboratory Surveillance

• Check electrolytes (sodium, potassium, magnesium), BUN, and creatinine every 1-2 weeks during active diuretic titration and GDMT optimization 1, 2
• Monitor for hypokalemia (common with loop diuretics), hyperkalemia (with MRA/RAAS inhibitors), and hyponatremia (with thiazides) 1, 2
• Recheck magnesium weekly until stable, then monthly 5
• Once stable on medications, transition to monitoring every 3-6 months 1

Clinical Assessment

• Daily weights to assess fluid status 1
• Monitor for signs of volume overload: peripheral edema, jugular venous distension, orthopnea 1
• Assess for symptomatic hypotension, especially when initiating or uptitrating RAAS inhibitors 1
• Monitor for signs of worsening renal function: decreased urine output, rising creatinine 1

Key Considerations in This Complex Patient

Renal Function and Diuretics

• eGFR 42 mL/min represents stage G3b CKD, which increases risk for diuretic resistance and electrolyte abnormalities 1
• Loop diuretics remain first-line; avoid thiazides as monotherapy with eGFR <30 mL/min (can use synergistically with loop diuretics) 1
• Continuous infusion of furosemide may provide better diuresis than bolus dosing in patients with moderate CKD, though twice-daily bolus dosing is also effective 6

Anticoagulation and Renal Function

• Renal dysfunction increases bleeding risk with anticoagulation; careful dose adjustment and monitoring required 1, 7
• With eGFR 42 mL/min, most DOACs can be used with appropriate dose reduction per manufacturer guidelines 1
• Renal function should be monitored regularly as further decline may necessitate switching to warfarin or LMWH 1

Age-Related Considerations

• At 84 years, start medications at low end of dosing range and titrate cautiously 1, 2
• Elderly patients are at higher risk for volume depletion, hypotension, and falls with aggressive diuresis 1, 2
• Assess for polypharmacy and potential drug interactions, particularly with NSAIDs (which should be avoided) 1, 2

Common Pitfalls to Avoid

• Do not stop RAAS inhibitors for modest creatinine increases (up to 30% is acceptable and often reflects hemodynamic changes rather than kidney injury) 1
• Avoid NSAIDs, which reduce diuretic efficacy and worsen renal function 1, 2
• Do not use potassium-sparing diuretics or potassium supplements without careful monitoring when initiating ACE inhibitors/ARBs 1
• Avoid excessive diuresis leading to intravascular volume depletion, which can precipitate acute kidney injury and hypotension 1
• Do not discharge with persistent congestion; ensure adequate decongestion before discharge to reduce readmission risk 1